Kornimate/medical-research-clean huggingface dataset:
biomechanical reconstruction of three different hip stem designs in hip dysplasia using a 3d ct-based planning software

Conditions: Dysplasia; Hip

Summary: a random population of 200 ct scans of pelvis and thigh in an adult population affected by hip dysplasia will be selected. the aim of this study is to evaluate the biomechanical reconstruction of the hip anatomy provided by three different hip stem designs in dysplastic cases, using a 3d ct based software for pre-operative planning.

pre-operative planning in hip arthroplasty with dedicated software is a useful guide to provide a better reconstruction of the biomechanical parameters of the replaced hip and to optimize the choice of component, improving the geometric understanding of the hip anatomy and the interaction between the native morphological structure and the prosthetic component. the use of a 3d ct-based software for pre-operative planning may provide a better knowledge of the hip anatomy, simulating the biomechanical parameters more closely than a 2d x-ray-based software. in addition, it is the only way to anticipate the correct interaction between the prosthetic components, or the combined anteversion, a key factor in preventing implant instability. severe hip deformities, like developmental hip dysplasia, may not be adequately reconstructed by every implant and 3d pre-operative ct may increase the three-dimensional anatomical knowledge of the hip, improving the choice of the correct implant and possibly reducing the possible consequences of intra and post-operative complications. therefore, the purpose of this study is to pre-operatively plan, in a random series of 200 native pelvis and thigh ct scans performed in patients with hip dysplasia, 3 different types of hip stem designs using the 3d hip-op software, with the aim of analyzing, on the ct simulations, the percentage of adequate reconstruction of the optimal biomechanical parameters (combined anteversion between 25°-50°, global offset not inferior to 12% of the native offset, leg lengthening not superior to 3 cm, sagittal and coronal tilt not superior to +/-5°, canal filling not inferior to 80%). the percentage of every stem design providing the optimal reconstruction in dysplastic hips (all the 5 parameters matched) will be assessed. the single parameters, especially the combined anteversion, the offset restoration and the leg lengthening, will be assessed for every simulation.

Eligibility criteria:
inclusion criteria: * definition of developmental hip dysplasia according to wiberg (center edge angle \<20°) * pre-operative ct scan extended from the fourth lumbar vertebra to the tibial plateaus exclusion criteria: * other types of hip pathologies * inadequate ct scans

Keywords: hip arthroplasty hip stem pre-operative planning combined anteversion offset developmental dysplasia of the hip
role of famotidine in the clinical improvement of covid-19 patients.

Conditions: Covid19

Summary: this study is aimed to investigate the effect of famotidine in the clinical recovery of covid-19 patients. covid19 is a worldwide pandemic. hence sars-cov-2 is a novel virus; there is no specific medication against it. like other countries of the world, besides antiviral drugs, immunosuppressive agents, and symptomatic therapy like h2 receptor blocker famotidine came to the limelight due to its role in reducing the symptoms of covid-19 patients. the study will include covid-19 participants to confirm by rt pcr or an hrct chest. detail history of each participant with comorbidity will be taken and will be examined carefully. the hospitalized patients admitted to the hdu/icu units will be enrolled in this study. critically ill patients who require ventilator support will not be included in this study. the outcome of the famotidine treatment will be evaluated and compared with a control group.


Eligibility criteria:
inclusion criteria: * sars-cov-2 infection confirmed by rt pcr or ct chest. * severe covid-19 patients require hospitalization under hdu/icu. exclusion criteria: * patients with severe and/or uncontrolled medical conditions with significantly compromised organ function. * patients who were hospitalized from the before due to other reasons. * contraindication / possible drug interaction with famotidine with existing therapy. * immunocompromised patients. * pregnancy, pulmonary tuberculosis, aids

Keywords: covid 19 famotidine bangladesh
observational study of subjects having routine recurrence screening for bladder cancer

Conditions: Bladder Cancer Recurrence

Summary: the purpose of this study is to detect recurrent bladder cancer using a combination of protein and dna biomarkers in urine


Eligibility criteria:
inclusion criteria: * intact bladder * scheduled for cystoscopy for transitional cell bladder cancer recurrence screening * urine donated prior to cystoscopy, bladder biopsy, chemotherapy, intravesical therapy, radiation or tur * must be willing to sign irb approved informed consent exclusion criteria: * history or current diagnosis of any cancer except transitional cell bladder cancer or basal cell cancer * known diagnosis of any autoimmune disease or hiv, hcv or hbv * history or current tb or any other active infection * subject has gross hematuria * receiving chemotherapy, intravesical therapy or radiation within 30 days of enrollment * any surgery except urologic within past 30 days
comparison of new contact lens with current marketed lens

Conditions: Myopia

Summary: the purpose of this study is to validate the clinical performance of a new contact lens design.

evaluate the clinical performance of its phoebe contact lenses (test) compared to the commercially available myday contact lenses (control).

Eligibility criteria:
inclusion criteria a person is eligible for inclusion in the study if he/she: * between and 18 and 35 years of age and has full legal capacity to volunteer * has had a self-reported oculo-visual examination in the last two years * has read and understood the information consent letter * is willing and able to follow instructions and maintain the appointment schedule * is correctable to a visual acuity of 20/25 or better (in each eye) with their habitual correction or 20/20 best corrected * has a contact lens refraction between -1.00d and -6.00d * cylinder power ≤ -0.75dc in spherical cylindrical refraction * currently wears soft contact lenses * is willing to wear lenses for a minimal of 8 hours a day and everyday during the course of the study * has clear corneas and no active ocular disease * has not worn lenses for at least 12 hours before the first visit exclusion criteria a person will be excluded from the study if he/she: * has never worn contact lenses before * is wearing monovision modality * has any systemic disease affecting ocular health * is using any systemic or topical medications that will affect ocular health * has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses * has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye * has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars * is aphakic * has undergone corneal refractive surgery * is participating in any other type of eye related clinical or research study
a follow-up study to assess long-term immunogenicity and safety of nicvax/placebo as an aid to smoking cessation

Conditions: Smoking Cessation; Nicotine Dependence

Summary: the purpose of the study is to obtain two year follow up data for subjects that received six vaccinations of nicvax in prior phase iii studies. no treatment will be administered. anti-nicotine antibody levels and safety data will be collected.

this study will follow subjects that participated in the nicvax phase iii studies for a second year. these predecessor studies, nabi-4514 (nct#00836199) and nabi-4515 (nct#01102114) evaluate the efficacy and safety of 6 vaccinations of nicvax or placebo as an aid to smoking cessation. the two phase iii studies are one year in duration, and subjects who complete these studies are eligible to enroll in nabi-4522. as the phase iii studies are ongoing, subject assignment to nicvax or placebo will remain masked. no intervention will be administered in nabi-4522. subjects will be followed for immunogenicity (anti-nicotine antibody level)and for safety.

Eligibility criteria:
inclusion criteria: * subjects who agree and sign consent to participate in this follow-up study. * subjects randomized and completed month 12 of the nabi-4514 or nabi-4515 study. * subjects who have received a total of 6 injections in nabi-4514 or nabi-4515. exclusion criteria: * anticipated inability to follow the study protocol through-out the study period. * known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder compliance or failure to sign informed consent. * subjects who intend to receive, or who are receiving an investigational new drug/device during the study.

Keywords: nicvax smoking cessation
a comparative evaluation of teg versus rotem for coagulopathy correction

Conditions: Liver Cirrhosis

Summary: studies comparing thromboelastography or rotational thromboelastometry versus standard coagulation tests are abundant. data comparing the two exclusively in a liver intensive care set up is limited. studies show that teg and rotem cannot be used interchangeably in trauma, liver transplant patients, but there is limited evidence of the same in critically ill cirrhotic patients. in this study, the investigators tried to demonstrate the comparison of blood products used to treat coagulopathy based on teg versus rotem algorithms in cirrhotic patients presenting with non variceal bleeding

thromboelastography (teg) and thromboelastometry( rotem) are point-of-care, global hemostasis assessment tests that measure the viscoelastic changes that occur during the hemostatic process. patients with cirrhosis have an imbalance of procoagulants and anticoagulants combined with alterations in fibrinolysis ,platelet number and function. point of care viscoelastic tests (teg ,rotem) demonstrate specific functional coagulation defects that can direct blood component transfusion therapy in cirrhosis, with clinical validation of individual parameters. studies comparing thromboelastography or rotational thromboelastometry versus standard coagulation tests are abundant. data comparing the two exclusively in a liver intensive care set up is limited. studies show that teg and rotem cannot be used interchangeably in trauma, liver transplant patients, but there is limited evidence of the same in critically ill cirrhotic patients. in this study, the investigators tried to demonstrate the comparison of blood products used to treat coagulopathy based on teg versus rotem algorithms in cirrhotic patients presenting with non variceal bleeding

Eligibility criteria:
inclusion criteria: * patients of liver cirrhosis with non variceal bleed exclusion criteria: 1. pregnant and postpartum patients 2. died within the first 24hours of admission. 3. variceal and postvariceal ligation ulcer bleed. 4. on anticoagulants or antiplatelets at the time of admission in icu 5. transfusion with blood products before admission to the icu.

Keywords: thromboelastography thromboelastometry nonvariceal bleeding
evaluation of corticosteroids use and clinical outcomes in hospitalized covid-19 patients: a retrospective study

Conditions: COVID-19 Pandemic; Morality

Summary: despite the recommendations to avoid using corticosteroids systematically for hospitalized coronavirus disease of 2019 (covid-19) patients, healthcare professionals used personalized treatments, including corticosteroids, as adjuncts to treat their patients due to their limited access to treatment options. this study aims to evaluate the use of corticosteroids among hospitalized covid-19 patients with all-cause mortality as the primary outcome and to assess the predictors of all-cause mortality associated with the characteristics of the patients and the corticosteroid regimens adopted.

a multicenter retrospective study was performed over three months targeting 422 covid-19 patients from six hospitals in lebanon. data were collected from patients' medical charts retrospectively and covered a period of one year (september 2020 to august 2021). the study sample included 422 patients, predominantly males, with 59% of cases classified as severe or critical cases. dexamethasone and methylprednisolone were the most used corticosteroids. around 22% of the patients died during hospitalization. after adjusting for covariates, performing a polymerase chain reaction test before admission increased the mortality rate by 424% compared to doing it at hospital admission (adjusted hazard ratio (ahr) 4.24, 95% confidence interval (ci) 1.35-13.3), with 18.11 times higher mortality rate among critical cases (ahr 18.11, 95% ci 9.63-31.05). exposure to side effects from corticosteroids increased the mortality rate by 514% compared to others (ahr 5.14, 95% ci 1.28-8.58). in particular, the mortality rate among patients having hyperglycemia dropped by 73% compared to others (ahr 0.27, 95% ci 0.06-0.98). corticosteroids are frequently used in treating hospitalized covid-19 patients. the all-cause mortality rate was higher among older and critical cases and lower among smokers and those treated for more than 7 days. research exploring the safety and efficacy of corticosteroids is required to allow better in-hospital management of covid-19 cases.

Eligibility criteria:
inclusion criteria: * adults patients admitted to the hospital after a confirmed covid-19 infection, irrespective of the stage and severity of the disease, were included in the study. exclusion criteria: * only those receiving corticosteroids as a treatment were in the study sample, with no preferences based on race or ethnicity.
acthar therapy for central nervous system sarcoidosis

Conditions: Sarcoidosis

Summary: there is a need for a more reliable, expeditious therapy that can be used as an alternative to glucocorticoids in severe central nervous system (cns) sarcoidosis. this study aims to provide evidence for effectiveness of acthar gel in cns sarcoidosis, and provide information about its safety and tolerability

central nervous system (cns) involvement is one of the most severe manifestations of sarcoidosis. sarcoidosis affecting the leptomeninges, spinal cord, or brain parenchyma portends a difficult course and frequently results in severe disability or death (1). treatment of moderate and severe cns sarcoidosis typically involves a combination of corticosteroids and cytotoxic agents such as methotrexate (2). unfortunately, most response rates are reportedly only in the 29-38% range for corticosteroids alone, and the effects of cytotoxic agents in sarcoidosis require up to 6 months to occur. a typical scenario is that patients are treated for prolonged periods with high dose glucocorticoids with suboptimal effectiveness despite development of substantial toxicities. some series report that cyclophosphamide or infliximab may be beneficial (3), but these approaches are limited by potentially severe toxicities, loss of effectiveness, or payor constraints. . acthar is a 39-amino acid peptide natural form of adrenocorticotropin hormone (acth) that was initially approved in 1952 by the fda. it has since been approved for 19 indications including respiratory sarcoidosis, multiple sclerosis, and infantile spasms.

Eligibility criteria:
inclusion criteria: * patient with sarcoidosis as defined by ats/ers/wasog (american thoracic society/european thoracic society/world association for sarcoidosis and other granulomatous disorders) * stable baseline immunosuppressive medications * moderate to severe disease as defined by at least one of the following criteria: * cranial nerve palsy * neurologic deficits related to intraparenchymal brain, spinal cord and/or cauda equina involvement * dural or leptomeningeal involvement of brain and/or spinal cord * hydrocephalus * seizures exclusion criteria: * diagnosis of any underlying neurologic disorder that would potentially confound interpretation of the study results * significant change in corticosteroid dose within the past 4 weeks, or other immunosuppressive medication within the past 6 months * evidence of current serious infection, or a history of chronic or recurring infections. * contraindication to high-dose corticosteroids (e.g. uncontrolled blood sugar). * allergies to pig-derived proteins * have a history of any opportunistic infection within 6 months prior to screening * history of malignancy.
thermal management in patients with interventional minimally invasive valve replacement

Conditions: Outcomes; Body Temperature

Summary: it is known that perioperative hypothermia can influence the postoperative outcome negatively. the most important complications are cardiac, increased blood loss with need for transfusion and a significantly increased wound infection rate. the thermal redistribution after the induction of anesthesia is on of the reasons for perioperative hypothermia. another reason is negative heat balance during surgery. further negative side effects of hypothermia are an increase of blood viscosity and thus a higher risk for thrombosis, coagulopathy and thus an increased risk of bleeding. the aim of the study is to evaluate if patients with a perioperative active thermal management during an interventional minimal invasive valve replacement have a significantly higher body temperature at the end of the operation than patients without an active thermal management. secondary outcome variables are complication rates, length of mechanical ventilation and length of icu treatment.


Eligibility criteria:
inclusion criteria: * patients, who need an interventional minimal invasive valve replacement * age ≥ 18 years * scheduled general anesthesia during intervention * no participation on another interventional study * signed informed consent exclusion criteria: * pregnant or breast feeding women * non-elective intervention * conversion to hlm * implantation of iabp * pre-existing decubitus * patients who are not able to sign informed consent

Keywords: hypothermia minimal invasive valve replacement
bariatric surgery and pharmacokinetics of atomoxetine

Conditions: Obesity, Morbid

Summary: changes to gastric ph, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. these factors are potentially influenced by bariatric surgery. little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. in this study the pharmacokinetic effects of bariatric surgery on atomoxetine are investigated.


Eligibility criteria:
inclusion criteria: * preparing to undergo gastric bypass or sleeve gastrectomy in central norway * being a norwegian citizen exclusion criteria: * having previously undergone resections in the gi-tract

Keywords: bariatric surgery gastrointestinal tract biological availability pharmacokinetics atomoxetine hydrochloride
phaco vs. phaco-elt vs. phaco-trabectome 12m

Conditions: Glaucoma; Cataract

Summary: this study compares efficacy (i.e. iop and hypotensive medications) of phaco alone vs. combined phaco plus excimer laser trabeculotomy vs. combined phaco plus trabectome.

glaucoma is one of the most common reasons for blindness. usually an elevated drain resistance is the reason, while aqueous humor production is normal. medical reduction of intraocular pressure (iop) is first line therapy in most cases. the gold standard of surgical treatment still is trabeculectomy (te) but te has a lot of drawbacks. in particular when glaucoma and cataract coexists, the investigators therefore prefer the combined procedure cataract extraction plus excimer laser trabeculotomy (elt) or plus trabectome. indication is cataract and a moderate elevated iop without medical therapy or a moderate cataract and elevated iop with medical therapy. the elt is performed by an aida xecl-excimer laser system (tui-laser ag, germering, 1,2 mj per burst, burst duration 16 ns, wave length 308 nm, spot diameter 200 µm). 10 foramina were made over 90 degrees of the anterior chamber angle. trabectome procedure is performed with the trabectome unit from neomedix. * trial with medical device * trial with surgical intervention

Eligibility criteria:
inclusion criteria: * all patients, which had phaco, phako/elt, or phaco-trabectome from 01/2008 until 12/2011, where screened 12 month after surgery exclusion criteria: * iop \>35 mmhg

Keywords: glaucoma cataract
prospective hyperthermia database in cancer patients (ht register)

Conditions: Hyperthermia; Cancer

Summary: this monocentric study registry records all cancer patients at the charité which are treated with hyperthermia to examine the therapeutic use of hyperthermia in cancer patients in the general application and to obtain an accurate risk-benefit balance after confinement in this database are the patients prospectively in order to complications, disease status and survival status tracked. furthermore there is the possibility in the course of this study to an optional take part in translational accompanying research with the aim of prognostic factors for response to hyperthermia treatment.

a total of 1000 patients with various diseases with the indication for hyperthermia in addition to standard oncological therapy (radiation therapy, chemotherapy, radiochemotherapy) will be included in this registry protocol.

Eligibility criteria:
inclusion criteria: * contrazeption with female patients at the capable of bearing children age * written agreement is present (dvh, ich-gcp) * patients, who participate at the same time in a interventional study, can nevertheless in this register study participate if this none exclusion criterion for the interventional study represents. * with children must the treatment with one of the gpoh agreed pattern take place exclusion criteria: * exclusion criteria for the hyperthermia (such as hip prosthesis in the therapeutic area, metal implants/marker, patients with cardiac pacemakers) * mental disease, what the proper study participation does not allow.

Keywords: hyperthermia e02.565 htregister